Agoracom: Small Cap Investment - Resverlogix Corp. - Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Reply New Message

Back To Forum List View

FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

KOO-KOO2

Apr 05, 2022 10:37AM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

golfyeti

Apr 05, 2022 10:50AM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

Investalot

Apr 05, 2022 11:28AM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

Apr 05, 2022 12:07PM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

KOO-KOO2

Apr 05, 2022 12:51PM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

Apr 05, 2022 01:56PM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

KOO-KOO2

Apr 05, 2022 05:52PM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

Apr 05, 2022 06:04PM

dlee38

Rank: Mail Room [?]

Points: 165 [?]

Votes: 3 Score: 4.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

in response to

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

KOO-KOO2

posted on Apr 05, 2022 06:13PM

If remdesivir is SoC, it has to be administered to eligible patients (unless there's a shortage).

5 Recommendations

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

KOO-KOO2

Apr 05, 2022 07:22PM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

Apr 05, 2022 08:13PM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

KOO-KOO2

Apr 06, 2022 06:57AM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients

dlee38

Apr 06, 2022 08:48AM

Re: FDA approves "empagliflozin" for reducing risk of cardiovascular death, hospitalization among adult HFpEF patients